Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxocobalamin at a New Concentration for Cobalamin-Related Remethylation Disorders
2024-516862-12-00Phase 3Authorised
- Sponsor
- Instituto de Investigación Sanitaria de Santiago de Compostela
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hydroxocobalamin in cobalamin-related remethylation disorder (CRRD) and vitamin B12 deficiency (2 arms), sponsored by Instituto de Investigación Sanitaria de Santiago de Compostela. Primary endpoint: Change in total homocysteine (tHcy) concentration. Planned start Jun 2025; status: authorised.
02
Drugs
hydroxocobalamin
03
Conditions
cobalamin-related remethylation disorder (CRRD)vitamin B12 deficiency
Beyond the preview
Go deeper on 2024-516862-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516862-12-00.